Does personalized medicine cut the mustard when it comes to treating cancer? Richard Smith, a former editor of the British Medical Journal, believes that it does not. Using the mustard metaphor, he shows how personalized medicine undermines the pharmaceutical industry’s profits. If the one-size-fits-all approach to prescribing cancer drugs were abandoned, drug companies would be forced to change their business model, most notably by increasing prices radically – or stop producing the drugs altogether.
View the original article here: Personalized Medicine’s Perverse Economics
Personalized medicine’s perverse economics
Donna Dickenson | Project Syndicate | December 21, 2012
{{ reviewsTotal }}{{ options.labels.singularReviewCountLabel }}
{{ reviewsTotal }}{{ options.labels.pluralReviewCountLabel }}
{{ options.labels.newReviewButton }}
{{ userData.canReview.message }}
GLP Podcasts & Podcast Videos | More... |
Infographics | More... |
Infographic: Could gut bacteria help us diagnose and treat diseases? This is on the horizon thanks to CRISPR gene editing
Humans are never alone. Even in a room devoid of other people, they are always in the company of billions ...
Most Popular
- Is tilapia a human-made freak that we should avoid — or an evolutionary rockstar?
- Re-examining 10 science-challenged studies suggesting GMOs are harmful
- Viewpoint: The organic food industry is a $180 billion marketing fraud
- Harnessing power of fungi could play key role in sucking CO2 from the atmosphere
- 23andMe adds 120 geographic regions to make genetic ancestry results more precise
- Injured MLB pitchers opt for unproven stem cell injections over Tommy John surgery
- Viewpoint: By engineering block on Vitamin A enhanced Golden Rice, Greenpeace ‘puts the whole environmental movement into disrepute’
- VIDEO: Are GM foods dangerous? Renowned science reporter takes on anti-GMO fundamentalists
- Embryos aren’t female by ‘default’ after all, study shows
- Y DNA: Redrawing map of Europe, North Africa and Middle East based on male lineages